A team of researchers from the University of Barcelona and the Bellvitge Biomedical Research Institute (IDIBELL) has identified a potential biomarker of Parkinson's disease progression.

Israeli scientists have identified a promising new factor in the pathology of Parkinson’s disease that could pave the way for ...

There’s still a lot we don’t know about how Parkinson’s disease develops. But one lifestyle intervention already has strong evidence behind it.

THE devastating illness to which James Parkinson called attention in 1817 has received a good deal of attention in the past ten years. Pharmaceutical chemists have developed rather a large number ...

A Risky Business: Why Do Some Parkinson's Disease Treatments Affect Decision Making? Sep. 24, 2024 — Parkinson's disease, a debilitating nervous system disorder, is treated with medications that ...

The Parkinson's Disease Activities of Daily Living Scale (PADLS) is a self-rated scale purpose-designed to assess difficulties in daily activities due to PD. [51] It consists of five mutually ...

AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about its neuroscience ...

pain and restless leg syndrome. Feeling tired and drowsy during the day is therefore also typical. Someone with Parkinson’s may notice that their sense of smell isn't as strong as it used to be ...

Parkinson’s disease (PD) is a progressive disorder of the nervous system. It primarily affects movement but can also lead to other symptoms, significantly impacting quality of life over time.

The Food and Drug Administration approved a drug produced by AbbVie for the treatment of late stage Parkinsons disease the company announced Thursday. The regulator approved Vyalev, also known as ...

Alzheimer’s disease and Parkinson’s disease are both neurodegenerative diseases. They’re similar in terms of symptoms, treatment, risk factors, and outlook. But there are also differences.

Out-of-pocket costs for drugs for neurologic diseases such as MS, Parkinson's and Alzheimer's disease are climbing sharply, ...